Teva posts Phase 3 SOLARIS analyses for Medincell-backed monthly olanzapine LAI at Psych Congress 2026
TEVA•TEVA•TEVA•TEVA•Medincell’s partner Teva presented new clinical and real-world data at Psych Congress 2026 in New Orleans.
Post hoc analyses from a late-stage schizophrenia trial supported durable disease control for Teva’s investigational once-monthly olanzapine injectable.
FDA action date for olanzapine LAI is expected in Q4 2026; the product remains unapproved.
Separate real-world evidence suggested UZEDY improved treatment continuity and reduced healthcare use versus some competing long-acting antipsychotics.
